RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: CMC
Five Keys to Successful Adaptive Trials
Running adaptive trials is not easy. However, in a world of skyrocketing drug development costs, these trials are set to become essential tools in any drugmaker’s repertoire, especially early in clinical development. A poorly done adaptive trial can not only … Continue reading
Posted in Clinical Trials, Statistics
Tagged adaptive trials, clinical trials, CMC, interim analysis, randomization, statistical analysis
Comments Off
DIA 2010 – Week in Review
The DIA 2010 Annual Meeting was a great success and Washington, DC was a great location. In addition to the thousands of industry attendees, the location made it possible for this year’s meeting to include FDA representatives from all areas … Continue reading
Posted in Conferences and Meetings, eCTD, FDA
Tagged adverse events, biomarkers, biotech, cell therapy, clinical development, clinical trials, CMC, comparative effectiveness, data standards, DIA, eCTD, FDA, globalization, in vitro diagnostics, personalized medicine, pharmacokinetics, Phase 1, Phase 2, RPS, study tagging files, transparency
2 Comments
Guidance for the Therapeutic Discovery Tax Credit
Credit you give yourself is not worth having. – Irving Thalberg For all you virtual biotechs and small start-up biotechs that survived the “Great Recession,” here is something to look forward to. I’ve mentioned the Therapeutic Discovery Tax Credit before, … Continue reading
Posted in Industry News
Tagged biomedical, biotech, CMC, FDA, GLP, IRS, Phase 1, Phase 2, pre-IND, tax credit
Comments Off
Switching from Paper to eCTD Submissions
Despite the many advantages of eCTD submissions, many smaller companies may still be reluctant to take the leap. Concerns over the costs of implementing an eCTD publishing system and the lack of in-house expertise are often the primary stumbling blocks. … Continue reading
Posted in eCTD
Tagged bookmarks, CFR Part 11, CMC, eCTD, Electronic Submissions Gateway, ESG, hyperlinks, IND, marketing application, NDA
1 Comment
